cp-55,940 has been researched along with am-356 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, P; Goutopoulos, A; Khanolkar, AD; Lin, S; Makriyannis, A; Papahadjis, D; Qin, C | 1 |
| Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
1 review(s) available for cp-55,940 and am-356
| Article | Year |
|---|---|
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
1 other study(ies) available for cp-55,940 and am-356
| Article | Year |
|---|---|
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Brain; Cannabinoids; Endocannabinoids; Guanosine 5'-O-(3-Thiotriphosphate); In Vitro Techniques; Mice; Polyunsaturated Alkamides; Radioligand Assay; Rats; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Serine Proteinase Inhibitors; Spleen; Structure-Activity Relationship; Tosyl Compounds | 1998 |